FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296449863> ?p ?o ?g. }

• W4296449863 endingPage "6656" @default.
• W4296449863 startingPage "6642" @default.
• W4296449863 abstract "Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-Hodgkin's lymphoma that occurs in the central nervous system. Although sensitive to chemotherapy, 35-60% of PCNSL patients still relapse within 2 years after the initial treatment. High-dose methotrexate (HD-MTX) rechallenge is generally used in recurrent PCNSL, especially for patients who have achieved a response after initial methotrexate (MTX) treatment. However, the overall remission rate (ORR) of HD-MTX rechallenge is about 70-80%. Additionally, the side effects of HD-MTX treatment endanger the health of patients and affect their quality of life.This is a retrospective study of patients with first relapse PCNSL at Huashan Hospital, Fudan University between January 2000 and November 2020. By comparing the clinical characteristics and radiological manifestations of first relapsed PCNSL patients with remission and non-remission after receiving HD-MTX rechallenge, we screened out the key factors associated with HD-MTX rechallenge treatment response, to provide some help for the selection of salvage treatment strategies for patients with recurrent PCNSL. Additionally, patients with remission after HD-MTX rechallenge were followed up to identify the factors related to progression-free survival of the second time (PFS2) (time from the first relapse to second relapse/last follow-up). The Kruskal-Wallis and Pearson chi-square tests were performed to examine the univariate association. Further, multivariable logistic regression analysis was used to study the simultaneous effect of different variables.A total of 207 patients were enrolled in the study based on the inclusion criteria, including 114 patients in the remission group (RG) and 81 patients in the non-remission group (nRG), and 12 patients were judged as having a stable disease. In Kruskal-Wallis and Pearson chi-square tests, progression-free survival rates for first time (PFS1) and whether the initial treatment was combined with consolidated whole brain radiotherapy (WBRT) were related to the response to HD-MTX rechallenge treatment, which was further validated in regression analysis. Further, after univariate analysis and regression analysis, KPS was related to PFS2.For PCNSL patients in their first relapse, HD-MTX rechallenge may be an effective salvage treatment. PFS1 and whether initial treatment was combined with consolidation WBRT were associated with HD-MTX rechallenge treatment response. In addition, patients with higher KPS at the time of the first relapse had a longer PFS2 after HD-MTX rechallenge treatment." @default.
• W4296449863 created "2022-09-20" @default.
• W4296449863 creator A5024300132 @default.
• W4296449863 creator A5036653211 @default.
• W4296449863 creator A5049863912 @default.
• W4296449863 creator A5067618472 @default.
• W4296449863 creator A5068313409 @default.
• W4296449863 creator A5072110295 @default.
• W4296449863 creator A5076409244 @default.
• W4296449863 creator A5082643397 @default.
• W4296449863 date "2022-09-17" @default.
• W4296449863 modified "2023-10-18" @default.
• W4296449863 title "Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse" @default.
• W4296449863 cites W1537483891 @default.
• W4296449863 cites W1568033114 @default.
• W4296449863 cites W1969695259 @default.
• W4296449863 cites W1976756323 @default.
• W4296449863 cites W1991427880 @default.
• W4296449863 cites W2003105250 @default.
• W4296449863 cites W2010984211 @default.
• W4296449863 cites W2024012030 @default.
• W4296449863 cites W2056132925 @default.
• W4296449863 cites W2082248517 @default.
• W4296449863 cites W2092929483 @default.
• W4296449863 cites W2095946215 @default.
• W4296449863 cites W2102995554 @default.
• W4296449863 cites W2104412135 @default.
• W4296449863 cites W2126959402 @default.
• W4296449863 cites W2131147182 @default.
• W4296449863 cites W2135838006 @default.
• W4296449863 cites W2149603266 @default.
• W4296449863 cites W2149741986 @default.
• W4296449863 cites W2149760873 @default.
• W4296449863 cites W2150587745 @default.
• W4296449863 cites W2157338776 @default.
• W4296449863 cites W2159708587 @default.
• W4296449863 cites W2181507900 @default.
• W4296449863 cites W2294816409 @default.
• W4296449863 cites W2314371091 @default.
• W4296449863 cites W2474317804 @default.
• W4296449863 cites W2493103431 @default.
• W4296449863 cites W2499675838 @default.
• W4296449863 cites W2598700764 @default.
• W4296449863 cites W2662929969 @default.
• W4296449863 cites W2758825568 @default.
• W4296449863 cites W2777109689 @default.
• W4296449863 cites W2777434070 @default.
• W4296449863 cites W2901857707 @default.
• W4296449863 cites W2903669497 @default.
• W4296449863 cites W2906198534 @default.
• W4296449863 cites W2923958958 @default.
• W4296449863 cites W2997386338 @default.
• W4296449863 cites W3031070597 @default.
• W4296449863 cites W3033112907 @default.
• W4296449863 cites W3070741114 @default.
• W4296449863 cites W3089038223 @default.
• W4296449863 cites W3094701717 @default.
• W4296449863 cites W3097339274 @default.
• W4296449863 cites W3109795060 @default.
• W4296449863 cites W3181884207 @default.
• W4296449863 cites W3215515670 @default.
• W4296449863 cites W32499833 @default.
• W4296449863 doi "https://doi.org/10.3390/curroncol29090522" @default.
• W4296449863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36135091" @default.
• W4296449863 hasPublicationYear "2022" @default.
• W4296449863 type Work @default.
• W4296449863 citedByCount "0" @default.
• W4296449863 crossrefType "journal-article" @default.
• W4296449863 hasAuthorship W4296449863A5024300132 @default.
• W4296449863 hasAuthorship W4296449863A5036653211 @default.
• W4296449863 hasAuthorship W4296449863A5049863912 @default.
• W4296449863 hasAuthorship W4296449863A5067618472 @default.
• W4296449863 hasAuthorship W4296449863A5068313409 @default.
• W4296449863 hasAuthorship W4296449863A5072110295 @default.
• W4296449863 hasAuthorship W4296449863A5076409244 @default.
• W4296449863 hasAuthorship W4296449863A5082643397 @default.
• W4296449863 hasBestOaLocation W42964498631 @default.
• W4296449863 hasConcept C126322002 @default.
• W4296449863 hasConcept C143998085 @default.
• W4296449863 hasConcept C144301174 @default.
• W4296449863 hasConcept C151956035 @default.
• W4296449863 hasConcept C2776694085 @default.
• W4296449863 hasConcept C2779338263 @default.
• W4296449863 hasConcept C2780775027 @default.
• W4296449863 hasConcept C2781059491 @default.
• W4296449863 hasConcept C2781173314 @default.
• W4296449863 hasConcept C38180746 @default.
• W4296449863 hasConcept C71924100 @default.
• W4296449863 hasConceptScore W4296449863C126322002 @default.
• W4296449863 hasConceptScore W4296449863C143998085 @default.
• W4296449863 hasConceptScore W4296449863C144301174 @default.
• W4296449863 hasConceptScore W4296449863C151956035 @default.
• W4296449863 hasConceptScore W4296449863C2776694085 @default.
• W4296449863 hasConceptScore W4296449863C2779338263 @default.
• W4296449863 hasConceptScore W4296449863C2780775027 @default.
• W4296449863 hasConceptScore W4296449863C2781059491 @default.
• W4296449863 hasConceptScore W4296449863C2781173314 @default.
• W4296449863 hasConceptScore W4296449863C38180746 @default.

• next